Amgen Appoints Francois de Carbonnel to the Company's Board of Directors Read more about Amgen Appoints Francois de Carbonnel to the Company's Board of Directors
District Court Affirms Patent Infringement Rulings and Finds That Amgen is Entitled to a Permanent Injunction against Roche Read more about District Court Affirms Patent Infringement Rulings and Finds That Amgen is Entitled to a Permanent Injunction against Roche
Amgen Receives Executive Summary from Independent Cochrane Collaboration Review of ESAs in Oncology Read more about Amgen Receives Executive Summary from Independent Cochrane Collaboration Review of ESAs in Oncology
Amgen to Present at UBS Global Life Sciences Conference Read more about Amgen to Present at UBS Global Life Sciences Conference
Amgen to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medical Devices Conference Read more about Amgen to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medical Devices Conference
Denosumab Osteoporosis Trial Finds Patients Transitioned from Alendronate (Fosamax(R)) to Denosumab Achieved Significantly Greater Gains in Bone Mineral Density versus Those Continuing on Alendronate Read more about Denosumab Osteoporosis Trial Finds Patients Transitioned from Alendronate (Fosamax(R)) to Denosumab Achieved Significantly Greater Gains in Bone Mineral Density versus Those Continuing on Alendronate
Biovitrum to Acquire Kepivance(R) and Stemgen(R) and Exclusively License Kineret(R) from Amgen Read more about Biovitrum to Acquire Kepivance(R) and Stemgen(R) and Exclusively License Kineret(R) from Amgen
Amgen to Present Important Clinical Trial Data at Two Key Congresses Read more about Amgen to Present Important Clinical Trial Data at Two Key Congresses
Amgen to Present at the Morgan Stanley Global Healthcare Unplugged Conference Read more about Amgen to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Amgen and Wyeth Statement on the FDA Safety Announcement Regarding Tumor Necrosis Factor (TNF) Blockers Read more about Amgen and Wyeth Statement on the FDA Safety Announcement Regarding Tumor Necrosis Factor (TNF) Blockers
